SynthesisBMC cancer2025
A systematic review and meta-analysis examining the relationship between hyperthyroidism or hypothyroidism and the probability of developing liver cancer.
Synthesis in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundObservational studies have reported inconsistent associations between hypothyroidism or hyperthyroidism and risk of liver cancer (LC). We therefore conducted a systematic review and meta-analysis to investigate the relationship between thyroid dysfunction and LC risk, and to explore the potential clinical implications of thyroid-related metabolic disturbances in liver carcinogenesis.
methodsTo identify eligible studies, we searched electronic databases including PubMed/Medline, ISI, Web of Science, and Scopus, up to March 2025. We also used fixed and random effects models to calculate effect sizes (ESs) and 95% confidence intervals (CIs) to detect association between hypothyroidism or hyperthyroidism, and the risk of LC.
resultsFive observational studies, with a total sample size of 3,206,891 individuals and 708 cases of LC, were included in this systematic review and meta-analysis. Pooling two effect sizes from case-control studies showed no significant association between hypothyroidism and risk of LC (Combined effect size: 1.31, 95% CI: 0.68–2.49, P = 0.413). However, by pooling two effect sizes from cohort studies it was found that there was an association between hypothyroidism and LC risk (Combined effect size: 1.45, 95% CI: 1.08–1.95, P = 0.012). Moreover, combining three effect sizes from cohorts revealed no significant association between hyperthyroidism (Combined effect size: 1.10, 95% CI: 0.90–1.34, P = 0.337) and risk of LC.
conclusionsThe present meta-analysis showed that there are associations between hypothyroidism and LC risk in the cohort studies. However, there is no association between hyperthyroidism and the risk of LC. These findings suggest that thyroid dysfunction, particularly hypothyroidism, may play a clinically relevant role in liver carcinogenesis through metabolic and hormonal pathways. Early detection and management of thyroid abnormalities might therefore be important in individuals at risk of liver cancer. REGISTRATION NUMBER: PROSPERO CRD42022331093.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.